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AS160 (TBC1D4) is a known Akt substrate that is phosphor­
ylated downstream of insulin action and that leads to regulated
traffic of GLUT4. As GLUT4 vesicle fusion with the plasma
membrane is a highly regulated step in GLUT4 traffic, we inves­
tigated whether AS160 and 14-3-3 interactions are involved in
this process. Fusion was inhibited by a human truncated AS160
variant that encompasses the first N-terminal phosphotyrosine­
binding (PTB) domain, by either of the two N-terminal PTB
domains, and by a tandem construct of both PTB domains of rat
AS160. We also found that in vitro GLUT4 vesicle fusion was 
strongly inhibited by the 14-3-3-quenching inhibitors R18 and
fusicoccin. To investigate the mode of interaction of AS160 and
14-3-3, we examined insulin-dependent increases in the levels
of these proteins on GLUT4 vesicles. 14-3-3� was enriched on 
insulin-stimulated vesicles, and its binding to AS160 on GLUT4
vesicles was inhibited by the AS160 tandem PTB domain con­
struct. These data suggest a model for PTB domain action on
GLUT4 vesicle fusion in which these constructs inhibit insulin-
stimulated 14-3-3� interaction with AS160 rather than AS160 
phosphorylation. 
AS160 (also called TBC1D4) is a Rab GTPase-activating pro­
tein (GAP)3 that is part of a subfamily of Rab GAPs that contain
a conserved TBC1 (Tre-2/Bub2/Cdc16) domain. AS160 was
first implicated as a regulator of insulin-stimulated GLUT4
traffic by Lienhard and co-workers (1–3), who discovered that
AS160 (which has a mass of 160 kDa) is a downstream substrate
of the kinase Akt. Insulin action, through activation of PI3K and
phosphatidylinositol 3,4,5-triphosphate generation, leads to
activation of phosphatidylinositol-dependent kinases PDK1
and PDK2, and both these activities are required for Akt acti­
vation. These activations of Akt then lead to phosphorylation of
AS160 on serine and tyrosine residues, most importantly Ser­
588 and Thr-642 (1, 4).
Evidence that AS160 is involved in regulation of GLUT4 traffic
includes use of a construct coding for a form of AS160 with 4
putative phosphorylatable serine and threonine residues mutated
to alanine (1). This AS160 –4P construct inhibits GLUT4 traffic in 
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insulin target cells, including fat and muscle (5, 6). The implication
from these studies is that AS160 is a negative regulator of vesicle
traffic of GLUT4 and that its conversion to a 4P mutant prevents
insulin action from switching off the GAP activity. AS160 –4P acts 
as a fully functional GAP, and this activity leads to termination of
the action of a downstream Rab that is also closely associated with
GLUT4 traffic (7, 8).
A mouse model in which a similar mutant (AS160 T649A)
has been expressed using a knock-in approach has been
described. This mutation leads to a glucose-intolerant pheno­
type with reduced insulin sensitivity and altered GLUT4 traffic
(9). Human insulin resistance has also been found to be associ­
ated with AS160 mutations. A human truncated variant of 
AS160 leads to insulin resistance and postprandial hyperinsu­
linemia (10). The effects of this truncation are associated with
impaired GLUT4 translocation in insulin target cells. As this
N-terminal truncation produces AS160 with an intact phos­
photyrosine-binding (PTB) domain, we have examined here
the functional and mechanistic consequences of AS160 PTB
domain expression by focusing primarily on the fusion of 
GLUT4 vesicles with the plasma membrane.
Extensive work by James and co-workers (11–13) and
MacKintosh and co-workers (14, 15) has provided evidence
that AS160 action is highly dependent on association with 14-3-3
proteins. The investigation by Larance et al. (11) led to the hypoth­
esis that AS160 is bound to GLUT4 vesicles in the basal state and 
dissociates from the vesicles when phosphorylated and when
bound to 14-3-3. Furthermore, although dissociation is evident,
this dissociation is not necessary for insulin-stimulated inactiva­
tion of the function of AS160 (12, 13). Support for the latter
notion is the observation that an AS160-GLUT4 construct, 
directly tied to vesicles by virtue of the transmembrane-associ­
ated GLUT4 component, is functionally inactivated by insulin
action without dissociation from the vesicles (13).
The site of action of AS160 in GLUT4 vesicle traffic has been 
partially resolved, and it has been found that the AS160 – 4P 
inhibits GLUT4 exocytosis but not its endocytosis (16). Further
resolution of its site of action within the exocytosis pathway has
been problematic. Some evidence supports a role in release of
GLUT4 vesicles from an intracellular reservoir compartment
(16), whereas other data suggest a role in docking of vesicles in
close proximity of the plasma membrane (16–19). The fusion
of GLUT4 vesicles at the plasma membrane is known to be a
highly insulin signaling-dependent step in GLUT4 traffic and
can be resolved in temporal detail using total internal reflection
fluorescence microcopy (18, 20–22). We have shown that these 
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final steps in insulin action on GLUT4 traffic can be reconstituted
using a cell-free in vitro approach (23). We have used this reduc­
tionist in vitro approach here to examine the role of AS160 in
fusion of GLUT4 vesicles. An advantage of the in vitro fusion assay
is that it reduces the complexity of the possible component
involvement in fusion and allows separation of this step from cel­
lular vesicle release that may influence vesicle docking.
In view of the importance of AS160 in glucose metabolism
and human insulin resistance, we have used cell-free in vitro 
assays to study the association of AS160 with 14-3-3 and the
role of this interaction in GLUT4 vesicle fusion with the plasma
membrane. In particular, we have investigated how protein
constructs of the PTB domains of AS160 act as fusion inhibitors 
and have evaluated the extent to which these inhibitory effects
occur through 14-3-3- and AS160-dependent generation of
fusion-competent GLUT4 vesicles. 
EXPERIMENTAL PROCEDURES 
DNA Constructs and Recombinant Protein Expression
and Purification—His-tagged N-terminal AS160(1–290),
AS160(230 –532), and AS160(1–532) constructs were ampli­
fied from a rat adipocyte cDNA library with primers containing
BamHI and HindIII restriction sites and cloned into the 
pET28a(�) vector (Novagen). His-tagged N-terminal con­
structs were all expressed in Escherichia coli strain 
Rosetta(DE3)pLysS by incubation with 0.1 mM isopropyl �-D­
thiogalactopyranoside for 4 h at  room temperature. Recombi­
nant proteins were purified on HisTrap columns using an
ÅKTA chromatography system (GE Healthcare) with a linear
imidazole gradient from 50 to 300 mM. The purified proteins
were dialyzed against PBS. The HA-AS160(1–532) construct
was obtained by PCR amplification with primers containing
KpnI and EcoRI restriction sites and cloned into the pHM6
vector (Roche Applied Science). The FLAG-AS160(1–532)
construct was obtained by PCR amplification with primers con­
taining NotI and BamHI restriction sites and cloned into the
p3�FLAG-CMV-10 expression vector (Sigma). The pCis2-HA­
GLUT4 construct was a gift from Dr. Samuel Cushman (24).
The human p3�FLAG-AS160 R363XTr construct was a 
kind gift from Dr. David Savage and has been described previ­
ously (10). The human p3�FLAG-AS160 (full-length) con­
struct was a kind gift from Dr. Gustav Lienhard and has been
described previously (25). FLAG-tagged AS160 R363X or full-
length AS160 was transfected into the human embryonic kid­
ney HEK293T cell line using a calcium phosphate transfection
method, and after 48 h of expression, the cells were lysed, and
the recombinant protein was purified by immunoprecipitation
with anti-FLAG antibody-agarose conjugate (Sigma). The 
recombinant protein was eluted from the beads with excess
3�FLAG peptide.
GST-14-3-3�, -�, and -� cDNA constructs were purchased
from Addgene (plasmids 13276, 13280, and 13279, respec­
tively). GST fusion proteins were expressed in E. coli strain 
DH5� by induction with 0.3 mM isopropyl �-D-thiogalactopy­
ranoside for 2 h at 37 °C.  The  recombinant proteins were puri­
fied on a glutathione-Sepharose column, and the eluted pro­
teins were dialyzed against PBS. 
Quantification of 14-3-3 Isoform mRNA Levels—Total RNA 
was extracted from rat brain and epididymal adipose tissue with
TriPure isolation reagent (Roche Applied Science) according to
the manufacturer’s instructions. The RNA was treated with 
DNase I to remove trace genomic DNA. 500 ng of total RNA,
treated with DNase I, was reverse-transcribed to cDNA using
the Superscript III First-Strand Synthesis Supermix kit for
qRT-PCR (Invitrogen). Quantitative real-time PCR was per­
formed with the StepOnePlusTM real-time PCR system
(Applied Biosystems) using iTaqTM SYBR� Green Supermix
with ROX (Bio-Rad) according to the manufacturer’s instruc­
tions. Primers were designed using Primer3 software (26) and
synthesized by Sigma. Primers were validated against a stan­
dard curve of varying amounts of brain cDNA, a tissue in which
all isoforms are known to be present. The comparative CT 
method was used to quantify the relative expression of 14-3-3 in
rat adipose tissue. 2.5 ng of adipose cDNA and 500 nM primers
(final concentration) were used in the final quantitative real-
time PCR. The following primer sequences were used: 14-3-3�, 
TAATGTTTGCTTCCGTGGTG (forward) and GGAGGGG­
GTCTTTTTCTTTTT (reverse); 14-3-3�, AGAGGCTATTG­
CGCTGTCAT (forward) and AAACTCCCCCAAAACA­
CCTC (reverse); 14-3-3�, CGAAATCAGCAAAGAGCACA 
(forward) and TGGTGCATTCTGGATCTCAT (reverse);
14-3-3�, GCGCTCAACTACTCCGTTTT (forward) and GA­
GTCCTCGTTCAGAGTGTCG (reverse); 14-3-3�, TGACAA­
CAGGGCGTTTCC (forward) and ACGAAGGCAGGAGGT­
GTAAGT (reverse); 14-3-3�, GCGGGGAATAAACAGG­
ATAA (forward) and AGCCTCACAAGTGCTCCAAG 
(reverse); and 14-3-3�-like, CCACTTCCTACCACCACTCC 
(forward) and CAGTCCAGTTCTCAGCCACA (reverse).
Assay of in Vitro GLUT4 Vesicle Fusion—The individual 
components of the in vitro fusion assay were prepared as
described previously (23). When recombinant proteins were
preincubated with the GLUT4 vesicles for 1 h at 4  °C  prior to
the fusion assay, the control vesicles were preincubated with an
equivalent amount of BSA. The in vitro fusion assay was per­
formed as described previously (23), and the extent of fusion at
5 min was compared with the maximum fusion obtained by
incubation at 37 °C for 30 min. 
Phosphoprotein Pulldown Assays with GST-14-3-3—Equal
amounts (7 �g) of GST-14-3-3�, -�, and -� fusion proteins were
prebound to glutathione-Sepharose. Fresh lysates from basal or
insulin-stimulated rat adipocytes were obtained by mainte­
nance for 20 min at 18 °C in phosphate lysis buffer (50 mM 
Na2HPO4 (pH 7.4), 150 mM NaCl, 2% octaethylene glycol dode­
cyl ether, and protease and phosphatase inhibitors). 500 �g of
cell lysate was incubated with immobilized 14-3-3 for 2 h at
4 °C. After extensive washing, bound protein was eluted by
incubating in elution buffer (20 mM reduced glutathione in 50 
mM Na2HPO4 (pH 8.5) and 150 mM NaCl). Eluted proteins were 
analyzed by SDS-PAGE, followed by electrotransfer and 
immunoblotting with anti-AS160 antibody (Millipore) and
anti-phospho-Akt substrate (PAS) antibody (Cell Signaling
Technology).
Quantification of AS160 and 14-3-3 Isoform Levels on 
GLUT4 Vesicles—Rat adipocytes at 40% cytocrit were main­
tained in the basal state or stimulated with 20 nM insulin for 20 
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FIGURE 1. Inhibition of in vitro fusion of GLUT4 vesicles with plasma membranes by N-terminal AS160 constructs and 14-3-3-quenching inhibitors. 
A, rat N-terminal AS160 PTB domain construct. Shown is the predicted domain organization of rat AS160 transcript variant 4 (LOC686547). The protein sequence was 
subjected to a domain search using the Pfam tool (42). The diamonds indicates predicted Akt phosphorylation sites. Ser-326 and Ser-350 in the rat sequence 
correspond to Ser-318 and Ser-341 in the human sequence. B, effect of the human truncated form of AS160 R363X on insulin-stimulated fusion activity. Immunoiso­
lated GLUT4 vesicles from basal cells were pretreated with increasing amounts of FLAG-AS160 R363X for1hat4  °Cbefore measuring the fusion activity in the presence 
of plasma membranes and cytosol from insulin-stimulated cells. Results are means � S.E. from four independent experiments. *, p � 0.05 (comparison with the insulin 
control). C, inhibition of fusion activity by rat N-terminal AS160 constructs. GLUT4 vesicle fusion activity was determined after pretreating immunoisolated GLUT4 
vesicles from basal adipocytes with increasing amounts of recombinant His-tagged N-terminal AS160(1–290), AS160(230–532), or AS160(1–532) for 1 h at 4 °C. Fusion 
activity was determined in the presence of plasma membranes and cytosol from insulin-treated adipocytes. Results are means � S.E. from four to eight independent 
experiments. *, p � 0.05 (comparison with the insulin control). D, dose response for the inhibition of fusion activity by His-AS160(1–532). Immunoisolated GLUT4 
vesicles isolated from basal cells were pretreated with increasing amounts of His-AS160(1–532) for 1 h at 4 °C before measuring the fusion activity in the presence of 
plasma membranes and cytosol from insulin-stimulated cells. Results are means � S.E. from four to five independent experiments. E, effect of 14-3-3-quenching 
inhibitors R18 and fusicoccin on the in vitro fusion activity. Insulin-stimulated cytosol was pretreated with the indicated concentrations of R18 or fusicoccin for 1 h at  
4 °C. Fusion activity was determined in the presence of plasma membranes and cytosol from insulin-treated adipocytes. Result are means � S.E. from five independent 
experiments. *, p � 0.05 (comparison with the insulin control). 
min at 37 °C. The cells were then homogenized and processed 14-3-3� (Millipore) antibody. For quantification purposes and
as described previously (27) to obtain a post-high density when required, a standard curve of the respective recombinant
microsome supernatant containing the GLUT4 vesicles. The protein was run on the same gel.
GLUT4 vesicles were purified by immunoisolation using a rab- Rat Adipocyte Transfection—Rat adipocytes were electropo­
bit anti-GLUT4 antibody (28) prebound to a maltose-binding rated with FLAG-AS160 (full-length) and HA-AS160(1–532)
protein-protein A construct (23) attached to amylose resin. according to the method described by Al-Hasani et al. (29).
After 2 h of  incubation, the amylose column was washed with Briefly, 200 �l of 50% cytocrit rat adipocytes was electroporated 
HES buffer (20 mM HEPES (pH 7.0), 0.5 mM EGTA, and 250 mM with 2 �g of pHM6-HA-AS160(1–532) and 0.1 �g of  
sucrose), and the GLUT4 vesicles were eluted in HES buffer p3�FLAG-AS160 (full-length). Cells were incubated for 12 h at
containing 40 mM maltose. Eluted proteins were resolved by 37 °C in DMEM supplemented with 3.5% BSA. After washing
SDS-PAGE and analyzed by Western blotting with the follow- with Krebs-Ringer HEPES buffer supplemented with 1% BSA
ing antibodies: anti-GLUT4 antibody (custom-made sheep and 200 nM adenosine, cells were left unstimulated or stimu­
anti-GLUT4 antibody raised against the same peptide as lated with 60 nM insulin for 20 min at 37 °C. The adipocytes
described previously (28)), anti-AS160 antibody, anti-PAS anti- were homogenized in HES buffer, and GLUT4 vesicles were
body, and anti-14-3-3�/� (Santa Cruz Biotechnology) or anti- isolated and analyzed as described above. 
16576 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286 •NUMBER 19 •MAY 13, 2011 
AS160 Links Insulin Action to GLUT4 Vesicle Fusion 
D
ow
nloaded from
 w
w
w
.jbc.org
 at University of Bath, on June 13, 2011
FIGURE 2. Analysis of the abundance of 14-3-3 isoforms in rat adipocytes and their interactions with AS160. A, quantitative real-time PCR analysis of the 
relative abundance of mRNA for the different known 14-3-3 isoforms in rat adipocytes. B, quantification of the 14-3-3�, -�, and -� proteins in rat adipocytes as 
detected by immunoblotting and quantified by comparison with a recombinant protein standard curve as illustrated in Fig. 4. C, comparison of the relative 
affinity of recombinant 14-3-3 isoforms �, �, and � for AS160. Equal amounts of GST-14-3-3�, -�, or -� immobilized on glutathione beads were incubated with 
total cell lysate prepared from basal (B) or insulin (I)-stimulated rat adipocytes. Relative amounts of AS160 pulled down by the recombinant proteins were 
detected by immunoblotting with anti-AS160 antibody. Results are means � S.E. from three independent experiments and with a representative immunoblot 
(D). E, comparison of the interaction of recombinant 14-3-3 isoforms �, �, and � with phosphorylated AS160. Equal amounts of GST-14-3-3�, -�, or -� immobi­
lized on glutathione beads were incubated with cell lysates prepared from basal or insulin-stimulated rat adipocytes. Relative amounts of phosphorylated 
AS160 pulled down by the recombinant proteins were detected by immunoblotting with anti-PAS antibody. Results are means � S.E. from three independent 
experiments with a representative immunoblot (F). 
Detection of Cell-surface HA-tagged GLUT4—HA-GLUT4 of cells at 40% cytocrit were then transferred into 96-well plates,
levels at the surface of transfected rat adipocytes were mea- and the fluorogenic �-galactosidase substrate fluorescein diga­
sured using an adaptation of previously described methods (29, lactoside (Invitrogen) was added to give a final concentration of
30). 5 h after electroporation with 0.1 �g of pCis2-HA-GLUT4 0.1 mM. The resulting fluorescence was measured every 15 s
and 0.4 �g of p3�FLAG-AS160(1–532), adipose cells were over a 60-min period in a PHERAstar FS multiwell plate reader
washed with Krebs-Ringer HEPES buffer supplemented with (BMG Labtech). The level of HA-GLUT4 present at the cell
1% BSA and 200 nM adenosine. Cells were maintained in the surface was then calculated from the fluorescence generated
basal state or stimulated with 60 nM insulin for 20 min at 37 °C. (rate of increase/mg of protein).
To stop further GLUT4 translocation, the cells were then Interaction of Full-length AS160 and N-terminal AS160(1–
treated with 2 mM KCN (final concentration) for 3 min at 37 °C. 532) in HEK293 Cells—HEK293 cells were transfected with 0.5 
The adipocytes were incubated for 1 h at 25 °C in the  presence �g of p3�FLAG-AS160 (full-length) and 2 �g of pHM6-HA­
of 1 �g/ml anti-HA antibody (Covance). After two washes with AS160(1–532) with Lipofectamine LTX (Invitrogen) according
Krebs-Ringer HEPES buffer, the cells were incubated for an to the manufacturer’s instructions. After expression for 18 h,
additional 1 h at 25  °C in the  presence of 1 �g/ml �-galactosi- cells were incubated with serum-free medium for 16 h and left 
dase-conjugated anti-mouse IgG (Southern Biotech). Aliquots untreated or stimulated with 50 ng/ml IGF1 for 20 min at 37 °C. 
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At the end of the incubation, cells were washed with PBS and 
lysed in Tris lysis buffer (50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 
150 mM NaCl, and 0.5% Triton X-100, supplemented with pro­
tease and phosphatase inhibitors). Lysates were cleared by cen­
trifugation at 17,000 � g for 20 min, and portions of the cleared
lysates were immunoprecipitated with anti-FLAG antibody-
agarose conjugate or anti-HA tag antibody (Abcam) conjugated
to protein G-agarose. Non-transfected cells were used as a con­
trol. Immunoprecipitated proteins were eluted with SDS sam­
ple buffer and analyzed by immunoblotting with anti-FLAG
antibody, anti-HA antibody, anti-pan-14-3-3 protein antibody
(Millipore), or anti-PAS antibody. 
RESULTS 
In Vitro GLUT4 Vesicle Fusion with the Plasma Membrane— 
We have developed an in vitro fusion assay that is reconstituted
from separately isolated fractions from rat adipose cells that are
maintained in the basal state or stimulated with insulin (23).
The separate isolation of fractions allows them to be mixed
such that GLUT4 vesicles from basal cells can be mixed with the 
plasma membrane and cytosol of either basal cells or insulin-
stimulated cells. With this approach, we found that GLUT4
vesicles from basal cells can be activated to become fusion-
competent using the plasma membrane from insulin-stimu­
lated but not basal cells (23). To examine whether AS160 has a
role in facilitating vesicle fusion and to investigate the mecha­
nism for the inhibitory effects of human AS160 truncation on
GLUT4 traffic (10), we examined the inhibitory effects of
protein constructs generated from AS160 N-terminal PTB
domains (Fig. 1A).
We tested the human protein construct AS160 R363X, com­
prising mainly the first PTB domain, as a potential inhibitor of
GLUT4 vesicle fusion. Addition of increasing protein concen­
trations to the fusion assay led to a progressive inhibition of fusion,
reaching a maximum �50% inhibition at the highest protein con­
centration tested (Fig. 1B). Protein constructs from rat AS160
incorporating the separate first (AS160(1–290)) and second
(AS160(230–532)) PTB domains inhibited vesicle fusion by �50% 
at the maximum protein level tested (Fig. 1C). A protein construct 
incorporating both tandem PTB domains (AS160(1–532))
inhibited fusion very potently, and the highest protein concentra­
tion tested inhibited fusion completely (Fig. 1D).
14-3-3 proteins can potentially interact with phosphorylated
AS160 (31), and we have therefore examined whether quench­
ing of 14-3-3 interaction can influence insulin-stimulated 
GLUT4 vesicle fusion with the plasma membrane target. The
R18 peptide, which is a pseudo-substrate for 14-3-3, led to inhi­
bition of in vitro fusion of basal GLUT4 vesicles with the insu­
lin-stimulated plasma membrane (Fig. 1E). A similarly potent
inhibition was observed upon treatment of the fusion compo­
nents with fusicoccin, a known 14-3-3-binding reagent (Fig.
1E). This compound is particularly potent in inhibition of the
interaction of 14-3-3 with the plant H�-ATPases (32).
Insulin Stimulates Specific Interactions between 14-3-3� and 
AS160 in Rat Adipocytes—To investigate the possible 14-3-3
isoform involved in insulin action on GLUT4 traffic and 
GLUT4 vesicle activation, we first determined the expression of
the message levels of 14-3-3 isoforms present in rat adipose 
FIGURE 3. Quantification of the amounts of 14-3-3 and AS160 present on 
GLUT4 vesicles. A, quantification of the amounts of 14-3-3 isoforms �, �, and 
� detected on GLUT4 vesicles (G4V) isolated from basal (B) or insulin (I)-stim­
ulated adipocytes. Results are means � S.E. from three independent experi­
ments. *, p � 0.05 (comparison of basal versus insulin-stimulated adipocytes 
for each isoform). B, representative immunoblots for the 14-3-3 isoforms and 
comparison with recombinant (Rec.) protein standard curves. C, quantifica­
tion of the amount of AS160 detected on GLUT4 vesicles isolated from basal 
or insulin-stimulated adipocytes. Results are means � S.E. from three inde­
pendent experiments. *, p � 0.05 (comparison of basal versus insulin-stimu­
lated adipocytes). D, representative immunoblots for AS160 and comparison 
with a recombinant protein standard curve. 
cells. 14-3-3� was found to be the most abundant isoform, with 
much higher message levels compared with 14-3-3 isoforms �, 
�, �, �, �, and � (Fig. 2A). However, the high level of 14-3-3� 
message was not reflected at the protein level, and quantitative
blotting against recombinant protein standards of 14-3-3�, -�, 
and -� revealed high protein levels of the � isoform (Fig. 2B). We
next compared the extent to which these three isoforms, as
GST constructs, could bind to and precipitate AS160 from rat
adipocyte cell lysates. Both 14-3-3� and 14-3-3� precipitated
AS160, but the � isoform was much more effective and precip­
itated higher amounts (Fig. 2, C and D). The levels of precipita­
tion by 14-3-3� were 15–17-fold greater from insulin-treated
lysates compared with basal lysates, reflecting the higher level of
phosphorylation and therefore more available sites for interaction
with 14-3-3. In addition, the � isoform relatively selectively pulled
down phosphorylated AS160 from adipocyte lysates as deter­
mined using an antibody that recognizes a wide range of phospho­
rylated Akt substrates (anti-PAS antibody) (Fig. 2, E and F). The
extent of precipitation of AS160 as determined by anti-PAS anti­
body blotting was also 15–17-fold greater in the lysates from insu­
lin-treated cells compared with basal cells.
14-3-3� Is Enriched on GLUT4 Vesicles— Although the ratios 
of 14-3-3� to 14-3-3� message and protein in rat adipocytes
were 10 and 0.7, respectively, the � isoform was found to be 
highly enriched on GLUT4 vesicles. Quantification of the pro­
tein levels against recombinant protein standards revealed that
the levels of the � isoform were 10 –15-fold higher than those of 
the � isoform. Furthermore, the levels of 14-3-3� were 3-fold 
higher on GLUT4 vesicles from insulin-treated cells compared
with basal cells (Fig. 3, A and B). The levels of AS160 were also
higher on GLUT4 vesicles from insulin-treated cells compared
with basal cells (Fig. 3, C and D). 14-3-3� binding to GLUT4
vesicles cannot be solely dependent on the concomitant bind-
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FIGURE 4. AS160(1–532) interacts with full-length AS160 and reduces the relative amount of 14-3-3� bound to AS160 and associated with GLUT4 
vesicles. A, primary rat adipocytes were cotransfected by electroporation with HA-tagged GLUT4 and FLAG-tagged AS160(1–532). After 5 hof  expression, cells 
were maintained in the basal state (B) or stimulated with 60 nM insulin (I). HA-GLUT4 present at the cell surface was detected after incubating the intact cells 
with anti-HA antibody for 1 h and detection using a �-galactosidase-coupled secondary antibody generating a fluorescent product. Results are means � S.E. 
from four replicates from a single experiment representative of two independent experiments. *, p � 0.05 (comparison of HA-GLUT4 alone versus HA-GLUT4 
plus FLAG-AS160(1–532)). B–D, primary rat adipocytes were cotransfected by electroporation with FLAG-tagged full-length AS160 and HA-tagged AS160(1– 
532). After 12 h of expression, cells were left unstimulated or stimulated with 60 nM insulin and then homogenized. GLUT4 vesicles (G4V) were immunoisolated, 
and the relative amounts of 14-3-3� (B), AS160 (C), and phosphorylated AS160 (pAS160; D) were detected by immunoblotting with anti-14-3-3�, anti-AS160, 
and anti-PAS antibodies, respectively. Results are means � S.E. from three independent experiments. E, representative immunoblots for data quantified in B–D. 
*, p � 0.05 (comparison of FLAG-AS160 alone versus FLAG-AS160 plus HA-AS160(1–532)). 
ing of AS160, as the levels of 14-3-3� associated with the vesicle 14-3-3 associated AS160 remains loosely associated with a ves­
were much higher than those of AS160. icle scaffolding and chaperoning protein network.
Our data on AS160 association with GLUT4 vesicles are con- AS160 PTB Domains Block 14-3-3� Recruitment to GLUT4 
sistent with a recent study by Sto¨ckli et al. (13), who showed Vesicles—The tandem PTB domain construct potently inhib­
that it is unnecessary for AS160 to dissociate from GLUT4 ves- ited insulin-stimulated (but not basal) GLUT4 translocation to
icles. However, working with immunoisolated GLUT4 vesicles the cell surface in the intact adipose cell (Fig. 4A). GLUT4 ves­
from an isolated low density microsome fraction of 3T3-L1 adi- icle loading with AS160 and its association with 14-3-3� may be
pocytes, Larance et al. (11) reported an insulin-dependent important in facilitating the fusion competency of these vesicles
AS160 dissociation from GLUT4 vesicles. By contrast, we and consequently inhibitory effects on cell-surface GLUT4.
found that, in rat adipocytes, there was an insulin-dependent The vesicles may also be a site of action for the inhibitory effects
increase in the level of AS160 associated with GLUT4 vesicles. of AS160 PTB domains. We therefore carried out a series of 
Differences in methodology for isolation of GLUT4 vesicles experiments in which rat adipocytes were cotransfected with a
may account for this discrepancy. Larance et al. (11) showed FLAG-tagged version of full-length AS160 together with the
that much of the low density microsome fraction of 3T3-L1 HA-tagged AS160 tandem PTB domains (AS160(1–532)). This
cells is a proteinaceous mixture of proteins that are only loosely transfection led to the association of large amounts of ex-
associated with intracellular membranes and that this material pressed FLAG-tagged AS160 on GLUT4 vesicles to an extent
is not recovered following membrane vesicle resuspension. We
prepared our vesicles from rat adipocytes using a mild isolation
that exceeded the levels of endogenous AS160 and was compa­
technique that does not involve sedimentation and resuspen-
rable with the level of endogenous 14-3-3. We subsequently
isolated the GLUT4 vesicles to determine the extent to which 
sion of membranes from a low density microsome fraction. Our the binding of 14-3-3�, the binding of FLAG-AS160, andvesicles are specifically associated with large amounts of FLAG-AS160 phosphorylation were perturbed by the tandem14-3-3� that we know is lost from the vesicles upon centrifuga- PTB domain construct. The association of 14-3-3� with insu­tion or high salt washes.4 It seems likely therefore that we do not lin-activated GLUT4 vesicles was significantly inhibited by theobserve loss of AS160 from vesicles on insulin action as the expression of the PTB domain construct (Fig. 4B). By contrast,
the cellular expression of the PTB domain construct did not
4 F. Koumanov and G. D. Holman, unpublished data. alter the level of FLAG-tagged AS160 and did not change the 
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FIGURE 5. AS160(1–532) interacts with full-length AS160, forms het­
erodimers, and inhibits 14-3-3 binding to AS160 in HEK293 cells. HEK293 
cells were cotransfected with FLAG-tagged full-length AS160 and 
HA-AS160(1–532). After 18 h of expression, cells were serum-starved, left 
unstimulated (basal (B)) or stimulated with 50 ng/ml IGF1, and then harvested 
and lysed in detergent. FLAG-AS160 or HA-AS160(1–532) was immunopre­
cipitated (IP) with anti-FLAG or anti-HA tag antibody, respectively. The immu­
noprecipitated proteins were subjected to SDS-PAGE and immunoblotted 
with anti-FLAG, anti-HA, anti-pan-14-3-3, or anti-PAS antibody. The relative 
levels of 14-3-3 (A) and FLAG-tagged phosphorylated AS160 (pAS160; B) 
pulled down were quantified and normalized to the level of expression of 
FLAG-tagged full-length AS160. Results are means � S.E. from three inde­
pendent experiments. *, p � 0.05 (comparison of FLAG-AS160 alone versus 
FLAG-AS160 plus HA-AS160(1–532)). C, representative immunoblots. 
level of FLAG-AS160 phosphorylation as detected with anti-
PAS antibody (Fig. 4, C and D). The levels of association of 
AS160 and 14-3-3� with GLUT4 vesicles were normalized for 
expression of GLUT4. The transfection experiments involved a
12-h incubation of the adipocytes, and the recovery of GLUT4
vesicles was found to be abnormally low from cells that were
treated with insulin after transfection. This can be seen by com­
paring Fig. 4E (from transfected adipocytes) with Fig. 3 (from
non-transfected adipocytes). The reason for this change is
unknown, but it leads to a greater reliance on normalization to
the recovered GLUT4 levels for estimating the levels of insulin-
dependent changes in vesicle-associated proteins.
As the main response to the PTB domain expression was a
reduced binding of 14-3-3�, we further investigated the direct
protein interaction between AS160, the tandem PTB domain
construct, and 14-3-3 isoforms. To do this, we chose the 
HEK293 cell expression system, which is known to be useful in
studying such interactions (10). We were able to show that het­
erodimer formation occurred between full-length AS160 and
the tandem PTB domains. Precipitation of expressed FLAG-
tagged AS160 with anti-FLAG antibody revealed that HA-
tagged PTB domains (AS160(1–532)) associated with the full-
length protein (Fig. 5C). Consistent with the data obtained with
rat adipocyte GLUT4 vesicles, the heterodimer formation did 
not alter IGF1-stimulated phosphorylation of FLAG-AS160
(Fig. 5, B and C) but significantly reduced the combination of
the heterodimer with endogenous 14-3-3 that was present in
the HEK293 cells and recognized by anti-pan-14-3-3 antibody
(Fig. 5A). Most 14-3-3 isoforms are present in HEK293 cells, but 
14-3-3� is the most abundant (33). This reduction in 14-3-3
association was related to heterodimer formation, as the PTB 
domain construct alone (which was phosphorylated) did not
lead to association with 14-3-3 (as detected in immunoprecipi­
tates using anti-HA antibody) (Fig. 5C). 
DISCUSSION 
Recent studies have revealed that the Rab GAP proteins
TBC1D1 and AS160 (TBC1D4) have important roles in the
metabolic pathways relevant to obesity and type 2 diabetes. A
mutant form of TBC1D1 occurs in a rare form of human obesity
(34, 35). Furthermore, truncation and loss of TBC1D1 in a
mouse strain have revealed that the presence of TBC1D1 con­
fers leanness when crossed with an obese and insulin-resistant 
mouse strain (36). In this mouse model, loss of TBC1D1 
reverses whole body insulin resistance and obesity in an artifi­
cial situation in which mice have high access to nutrients. Inter­
estingly, differences in TBC1D1 gene sequence have been
genetically linked to differences in growth and metabolic activ­
ity occurring within chicken lines bred for high meat content or
egg-laying activity (37). The mouse model in which a non-phos­
phorylatable mutant of AS160 (AS160 T649A) has been 
expressed leads to a glucose-intolerant phenotype with reduced
insulin sensitivity and altered GLUT4 traffic (9). Human insulin
resistance has also been found to be associated with AS160 
mutations. Families with AS160 variants including N1206S,
N655Y, and N785K have been identified and may contribute to
varying degrees of insulin resistance. However, complete co­
segregation with the phenotype was difficult to achieve in stud­
ies on these families (38). In addition, a human truncated vari­
ant of AS160 leads to acanthosis nigricans and postprandial
hyperinsulinemia (10). The effects of this truncation are asso­
ciated with impaired GLUT4 translocation in insulin target
cells. In 3T3-L1 cells, expression of this truncated mutant leads 
to elevation of basal and reduction of insulin-stimulated 
GLUT4 traffic (10). We have confirmed here that the AS160
tandem PTB domain construct inhibits insulin-stimulated 
GLUT4 translocation to the cell surface in rat adipose cells.
We found inhibition of fusion by the PTB domains of AS160
and by the 14-3-3-quenching inhibitors R18 and fusicoccin,
thus identifying the fusion reaction as an important site for
action of these proteins, their mutants, and truncated forms.
Previous studies have suggested a prefusion role for AS160 in
which the delivery of GLUT4 vesicles to the vicinity of the
plasma membrane prior to initiation of fusion is one of the
means by which translocation is activated by insulin action (3,
16, 19). In total internal reflection fluorescence studies that
allow a distinction between vesicle docking and fusion, it has
been suggested that a block in docking of GLUT4 vesicles by the
AS160–4P construct indirectly affects downstream fusion (17).
Insulin action on fusion machinery beyond and downstream of
AS160 has been proposed (18, 19), possibly involving the motor
protein Myo1c (39, 40). The inhibition of GLUT4 vesicle dock-
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FIGURE 6. Model for inhibitory effects of AS160 N-terminal PTB domain 
constructs and 14-3-3-quenching reagents on GLUT4 vesicle fusion. 
A, insulin-stimulated generation of fusion-active GLUT4 vesicles (G4V). Insulin 
action leads to AS160 phosphorylation and 14-3-3� binding and conse­
quently generation of a GLUT4 vesicle Rab in an active GTP-loaded form. B, 
proposed mechanism for fusion inhibition by the N-terminal tandem PTB 
domain construct AS160(1–532). It is proposed that heterodimer formation 
with full-length AS160 prevents 14-3-3� binding. The R18 peptide prevents 
14-3-3� binding through direct quenching reaction. PM, plasma membrane. 
ing and fusion with the plasma membrane by the PTB domain
constructs of AS160 revealed here provides direct evidence that
AS160 itself is required for in vitro docking and fusion, where
release from intracellular compartments is not occurring.
Our studies on the mechanism by which the PTB domain 
constructs and 14-3-3-quenching compounds inhibit the 
fusion reaction have led us to the discovery that 14-3-3� is 
highly enriched on GLUT4 vesicles and has marked selectivity
for interaction with phospho-AS160. The combination of
AS160 with 14-3-3� appears to be critical, and the PTB 
domains of AS160 can act as inhibitors of fusion by inhibiting
this interaction. This inhibitory effect of the PTB domains on
14-3-3� binding occurs on GLUT4 vesicles but can also be
reproduced in studies on direct protein-protein interaction.
These data led us to propose a model for regulation of
GLUT4 vesicle fusion in which insulin-stimulated 14-3-3� 
interaction, but not AS160 phosphorylation alone, generates a
fusion-activating GAP-inactive form of AS160 (Fig. 6A). We
suggest that the PTB domain constructs form heterodimers
with endogenous AS160 and that this interaction prevents the
binding of 14-3-3 to phosphorylated AS160 (Fig. 6B). There­
fore, AS160 remains in its GAP-active form, the associated Rab 
remains in the GDP form, and fusion activity is therefore low.
The basis for the R18 inhibition of fusion is likely to be due to 
AS160 Links Insulin Action to GLUT4 Vesicle Fusion 
quenching of all available 14-3-3, so, again, although AS160 is
phosphorylated, the GAP is active, the associated Rab remains
in its GDP form, and fusion activity is therefore low. Our data
appear to be inconsistent with a receptor-blocking mode of
action of the fusion inhibitory PTB domains. If interaction with
a receptor, such as IRAP (Insulin-regulated aminopeptidase)
(11, 41), were blocked by the PTB domain constructs, then
AS160 would be unable to be recruited to the vesicles, and the 
vesicle Rab would be expected to be in the fusion-facilitating
and fusion-active form. Fusion would be expected to be high,
but this has not been observed. In contrast to a study on GLUT4
vesicles in 3T3-L1 cells (11), we found that, in rat adipose cells,
AS160 is continuously associated with GLUT4 vesicles and that
insulin action does not lead to its dissociation. However, our 
data support the hypothesis that 14-3-3 interaction with AS160
is largely responsible for its functional inactivation as proposed
by Ramm et al. (12).
In conclusion, this investigation of the inhibitory effects of
N-terminal PTB domain constructs of AS160, including a 
human truncated variant, has revealed that the inhibitory PTB
domains stop the loading of vesicles with 14-3-3� but do not 
stop AS160 phosphorylation. This suggests that phosphoryla­
tion alone, without 14-3-3� combination, does not generate
GLUT4 vesicles that can fuse with the insulin-activated plasma
membrane in adipocytes. The emerging roles of the Rab GAPs
TBC1D1 and AS160 (TBC1D4) in the control of whole body
and muscle glucose metabolism in human subjects with obesity
and type 2 diabetes indicate that further studies on the roles of
both of these proteins in the process of GLUT4 vesicle fusion in
muscle are warranted. 
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